Printed from Voxsanity (voxsanity.com.au) — NCT07616063 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Alzheimers Disease
Alzheimer's Disease Trial, Not Yet Recruiting
NCT07616063
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Native French speakers.
- People who are able to move around independently at least within their neighbourhood (based on a mobility assessment called the LSA-F).
- People who are enrolled in, or covered by, a French social security system.
- Patients in Subgroup A1 and healthy volunteers in Group C: people who have been fully informed about how the research is organised and have signed a written consent form.
- Patients in Subgroups A2 and A3, and companions in Group B: people who have been fully informed about the research and have agreed to take part.
- Patients (Group A): people aged between 55 and 85 years old.
- Patients (Group A): people who have been given a diagnosis of probable Alzheimer's disease based on recognised medical diagnostic standards (called NINCDS-ADRDA criteria).
- Patients (Group A): people who score 4 or below on a medical scale used to assess memory problems related to blood flow in the brain (called the Hachinski Ischemic Scale).
- Patients (Group A): people who score 20 or higher on a standard memory and thinking test called the MMSE (Mini Mental State Examination).
- Patients (Group A): people who are taking Alzheimer's-specific medications (anticholinesterase or memantine) must have been on a stable dose for more than 15 days.
- Patients (Group A): people who are able to walk on their own without human assistance or mobility aids, except for a simple walking cane.
- Caregivers (Group B): people who regularly care for a person with dementia who is enrolled in Group A, with at least 10 hours of contact per week across a minimum of 3 days per week.
- Healthy volunteers (Group C): people aged between 55 and 85 years old.
- Healthy volunteers (Group C): people who are able to walk on their own without human assistance or mobility aids, except for a single walking cane.
- Healthy volunteers (Group C): people whose score on the MMSE memory and thinking test falls within the normal range according to French cognitive assessment standards (called GRECO standards).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are under a legal protection order, such as guardianship or court-appointed supervision.
- People who are not able to give their own informed consent.
- People who have been deprived of their freedom by a court or government decision, or who are receiving certain types of compulsory psychiatric care under French law.
- People who are able to give consent but cannot read French.
- People who are able to give consent but cannot write.
- Cases where one member of a patient–caregiver pair does not wish to take part in the study.
- Patients in Subgroup A1 and healthy volunteers in Group C: people who have a sensory or language problem that would interfere with completing the study tasks.
- Patients in Subgroup A1 and healthy volunteers in Group C: people with a history of moderate or severe head injury that involved a loss of consciousness.
- Patients in Subgroup A1 and healthy volunteers in Group C: people whose medication affecting mood or brain function has been changed within the 48 hours before testing.
- Patients in Subgroup A1 and healthy volunteers in Group C: people with chronic alcoholism.
- Patients in Subgroup A1 and healthy volunteers in Group C: people with severe depression, defined as a score of 10 or higher on a standard depression screening tool called the GDS-15.
- Patients in Subgroup A1 and healthy volunteers in Group C: people with other significant psychiatric or neurological conditions (for patients, this exclusion does not apply to Alzheimer's disease itself).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Phone: 0383153596
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 November 2026
Where this trial is recruiting
🇫🇷 France
Primary endpoints
French version of the QOS Score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.